{
    "clinical_study": {
        "@rank": "89088", 
        "arm_group": [
            {
                "arm_group_label": "Dexmedetomidine", 
                "arm_group_type": "Experimental", 
                "description": "Bolus Dose:0.4 mcg/kg Infusion Rate:.0.4mcg/kg/h. The study involves the use of dexmedetomidine infusion intraoperatively during thoracic procedures with discontinuation in the immediate postoperative period."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Bolus Placebo:Infusion. The study involves the use of placebo infusion intraoperatively during thoracic procedures with discontinuation in the immediate postoperative period."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if the drug, Dexmedetomidine (also known as Precedex),\n      can reduce pain for patients having Thoracic Surgery and therefore reduce the amount of\n      opioid drug needed after surgery. It is a drug that is already approved by the FDA (Food &\n      Drug Administration) for use as a sedative in hospitals and is currently used in the\n      investigators Intensive Care Unit for this purpose. The investigators want to investigate if\n      it also has pain relieving properties."
        }, 
        "brief_title": "Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery", 
        "condition": "Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients (>=21 years old) scheduled for Thoracic Surgery\n\n        Exclusion Criteria:\n\n          -  2nd or 3rd degree heart block as assessed by preoperative EKG\n\n          -  Use of dexmedetomidine within 28 days prior to day of surgery\n\n          -  Use of long acting opioids pre-operatively 28 days prior to day of surgery\n\n          -  Current or past diagnosis of a Major Psychiatric disorder precluding adequate outcome\n             responses such as Schizophrenia, dementia, delirium etc. as recorded in the\n             Pre-Operative Record.\n\n          -  Documentation of congestive heart failure and Ejection fraction < 30% if recorded in\n             the Pre-Operative Record.\n\n          -  Planned use of an epidural for surgery or post-operative pain relief\n\n          -  Contraindication to use of NSAID, Acetaminophen or IV opioids.\n\n          -  Any known hypersensitivity to dexmedetomidine\n\n          -  Pregnant or breastfeeding\n\n          -  Abnormal liver function tests as related to the MSK guidelines for use of IV\n             Acetaminophen\n\n        Yes or NO?; Is ALT greater than 2 x Upper Limit of Normal (> 75 U/L)?\n\n          -  Abnormal renal function tests as related to contraindications to use of IV Ketorolac\n\n        Yes or No?; Is Serum Creatinine Clearance < 1.5 mmol/L?"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "280", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973452", 
            "org_study_id": "13-163"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dexmedetomidine", 
                "intervention_name": "Dexmedetomidine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexmedetomidine", 
                "Analgesics, Opioid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Dexmedetomidine", 
            "Opioid", 
            "Thoracic Surgery"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Alessia Pedoto, MD", 
                "phone": "212-639-6840"
            }, 
            "contact_backup": {
                "last_name": "Vivek T. Malhotra, MD", 
                "phone": "212-639-6851"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center 1275 York Avenue"
            }, 
            "investigator": {
                "last_name": "Alessia Pedoto, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Masked Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery", 
        "overall_contact": {
            "last_name": "Alessia Pedoto, MD", 
            "phone": "212-639-6840"
        }, 
        "overall_contact_backup": {
            "last_name": "Vivek T. Malhotra, MD", 
            "phone": "212-639-6851"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Alessia Pedoto, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "total opioid equivalents used postoperatively as measured by the total opioid administered in approximately the first 4 hours", 
            "measure": "total opioid administered", 
            "safety_issue": "No", 
            "time_frame": "up to 4 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973452"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "as measured by change in Pain Numerical Rating Scale (NRS) preoperatively to postoperatively at rest and with activity (such as coughing).", 
                "measure": "Improves analgesia", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }, 
            {
                "description": "as measured by incidence of recorded nausea, the use of antiemetics and RASS sedation scores, respectively.", 
                "measure": "Results in fewer cumulative episodes of nausea or antiemetic doses and/or sedation", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}